ArticleMedicine2025
S100A12 as a key biomarker in a neutrophil-associated gene prediction model for sepsis diagnosis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neutrophil Heterogeneity: Molecules to Cellular Behavior.Life (Basel, Switzerland) · 2026Review
- Multi-cohort transcriptomics integration for building and validating a diagnostic model of peripheral blood septic shock.Frontiers in immunology · 2026Article
- S100A12 drives inflammatory and metabolic reprogramming in sepsis-associated acute kidney injury.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection. As a leading cause of mortality in intensive care units patients, it still lacks sensitive biomarkers. Therefore, this study aimed to develop a diagnostic model for sepsis and identify key driver biomarkers. Using single-cell RNA sequencing (scRNA-seq) data from the GEO database, we constructed a diagnostic model through 113 machine learning (ML) frameworks, supplemented with Shapley additive explanations (SHAP) analysis to identify pivotal genes. Results revealed a significant increase in myeloid cells, particularly neutrophils, in the peripheral blood of sepsis patients. Screening identified 70 upregulated and 762 downregulated neutrophil-associated genes, which were intersected with differentially expressed genes (DEGs) between healthy controls and sepsis patients, yielding 13 overlapping genes - including S100A12 - as potential drivers. These 13 genes were incorporated into 113 ML models. The Random Forest (RF) model, which included S100A12, PIK3AP1, HLA-DMB, and RETN, achieved the highest mean C-index with fewer features. Its robust diagnostic performance was validated using receiver operator characteristic curves, calibration curves, and decision curve analysis. SHAP analysis highlighted S100A12 as the most influential driver gene and identified theophylline, aspirin, and aminophylline as potential targeting compounds. In conclusion, sepsis patients show increased peripheral neutrophils, an RF model based on 4 neutrophil-associated genes demonstrates strong diagnostic ability, and S100A12 serves as a key biomarker for sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.